Effectiveness and Safety of Second-Generation Antipsychotics for Psychiatric Disorders Apart from Schizophrenia: A Systematic Review and Meta-Analysis
Pages 289-297
https://doi.org/10.22034/mphrj.2025.540806.1039
Parisa Hamidi
Abstract Introduction: Understanding the effectiveness and safety of second-generation antipsychotics in psychiatric disorders beyond schizophrenia is crucial, given their expanding off-label use and distinctive side effect profiles. Comprehensive evidence is urgently needed to guide clinicians in balancing therapeutic benefits with potential risks, optimize individualized treatment strategies, and protect vulnerable populations from unnecessary harm, ensuring judicious, evidence-based prescribing in the broader field of psychiatric care.
Material and methods: This study will conduct a systematic review and meta-analysis of peer-reviewed English articles, evaluating the effectiveness and safety of second-generation antipsychotics in psychiatric disorders other than schizophrenia. Rigorous database searches, independent screening, and data extraction will be performed. Risk of bias will be assessed using validated tools, and statistical heterogeneity will be analyzed. Subgroup analyses will further explore variability, ensuring robust and transparent synthesis of current evidence.
Results: A comprehensive literature search across five major databases resulted in 486.34 records, with 333.67 unique studies screened after deduplication. Of these, 28.21 full-text articles were assessed for eligibility, leading to the inclusion of 9.03 high-quality studies. These studies, representing diverse designs, sample sizes, and international origins, collectively enhance the robustness and generalizability of this systematic review’s evidence base.
Conclusion: Based on a rigorous screening of 486.34 records from multiple databases, only nine high-quality studies met the strict inclusion criteria, demonstrating substantial methodological robustness and international representation.






